Last reviewed · How we verify
Sulopenem Etzadroxil/Probenecid
Sulopenem etzadroxil/probenecid is a combination antibiotic that works by inhibiting bacterial cell wall synthesis and reducing the reabsorption of the antibiotic in the kidneys.
Sulopenem etzadroxil/probenecid is a combination antibiotic that works by inhibiting bacterial cell wall synthesis and reducing the reabsorption of the antibiotic in the kidneys. Used for Complicated urinary tract infections (cUTIs), including pyelonephritis.
At a glance
| Generic name | Sulopenem Etzadroxil/Probenecid |
|---|---|
| Also known as | Individual Patients, Oral sulopenem |
| Sponsor | Iterum Therapeutics, International Limited |
| Drug class | carbapenem antibiotic |
| Target | bacterial cell wall synthesis |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Sulopenem etzadroxil is a prodrug that is converted into sulopenem, a carbapenem antibiotic that inhibits bacterial cell wall synthesis. Probenecid reduces the reabsorption of sulopenem in the kidneys, increasing its concentration in the urine and allowing for more effective treatment of urinary tract infections.
Approved indications
- Complicated urinary tract infections (cUTIs), including pyelonephritis
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
Key clinical trials
- Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents (PHASE1)
- Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women (PHASE3)
- Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection
- Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents (PHASE1)
- Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women (PHASE3)
- Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults (PHASE3)
- Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: